Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus candonilimab in advanced colorectal cancer
ChiCTR2200065303Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial Hospital of Traditional Chinese Medicine
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fruquintinib and cadonilimab in colorectal cancer (CRC), sponsored by Jiangsu Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Progression-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
fruquintinibcadonilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2200065303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065303.